Programmed cell death 1. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Pembrolizumab CHEMBL3137343 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 622 |
| Nivolumab CHEMBL2108738 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 276 |
| Tislelizumab CHEMBL4297840 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 237 |
| Sintilimab CHEMBL4297829 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
✓ Both | 208 |
| Toripalimab CHEMBL4297843 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
✓ Both | 189 |
| Camrelizumab CHEMBL4297715 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
ChEMBL only | 107 |
| Cadonilimab CHEMBL4594456 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 85 |
| Serplulimab CHEMBL4594550 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
✓ Both | 82 |
| Cemiplimab CHEMBL4297723 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 68 |
| Dostarlimab CHEMBL4298124 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
✓ Both | 42 |
| Pucotenlimab CHEMBL4650472 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 34 |
| Zimberelimab CHEMBL4297856 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 30 |
| Penpulimab CHEMBL4297571 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 19 |
| Budigalimab CHEMBL4297858 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
ChEMBL only | 13 |
| Cetrelimab CHEMBL4298001 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
ChEMBL only | 13 |
| Balstilimab CHEMBL4297877 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
✓ Both | 11 |
| Retifanlimab CHEMBL4298037 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
✓ Both | 8 |
| Spartalizumab CHEMBL4297831 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
✓ Both | 5 |
| Enlonstobart CHEMBL5315040 |
Binds PDCD1 Primary target Antibody |
Guide to Pharmacology only | 4 |
| Finotonlimab CHEMBL4650516 |
Programmed cell death protein 1 inhibitor Inhibitor Antibody |
✓ Both | 3 |
| Sasanlimab CHEMBL4298191 |
Programmed cell death protein 1 antagonist Antagonist Antibody |
ChEMBL only | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Colorectal cancer | 14 | Phase 3 |
| Non-small cell lung carcinoma | 13 | Phase 3 |
| Breast cancer | 12 | Phase 3 |
| Gastric adenocarcinoma | 12 | Phase 3 |
| Gastroesophageal junction adenocarcinoma | 11 | Phase 3 |
| Hepatocellular carcinoma | 11 | Phase 3 |
| Classic Hodgkin lymphoma | 10 | Phase 3 |
| Gastric cancer | 10 | Phase 3 |
| Head and neck squamous cell carcinoma | 10 | Phase 3 |
| Cancer | 9 | Phase 3 |
| Cervical cancer | 9 | Phase 3 |
| Esophageal squamous cell carcinoma | 9 | Phase 3 |
| Biliary tract cancer | 7 | Phase 3 |
| Esophageal cancer | 7 | Phase 3 |
| Clear cell renal carcinoma | 6 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
